Results 31 to 40 of about 125,678 (274)

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. [PDF]

, 2019
The gold standard for a definitive diagnosis of Parkinson disease (PD) is the pathologic finding of aggregated α-synuclein into Lewy bodies and for Alzheimer disease (AD) aggregated amyloid into plaques and hyperphosphorylated tau into tangles.
Brundin, P, Cambi, F, Espay, AJ, Fasano, A, Fernandez, HH, Gan-Or, Z, Greenamyre, JT, Josephs, KA, Kauffman, MA, Lang, AE, Leverenz, JB, Litvan, I, Marsili, L, Mata, IF, Merola, A, Morgante, F, Perry, G, Sardi, SP, Savica, R, Schwarzschild, MA, Sherer, T, Simon, DK, Standaert, DG, Tanner, CM, Vizcarra, JA, Yamasaki, TR, Zabetian, CP   +26 more
core   +3 more sources

Additional file 2: of Meta-analysis of risk factors for Parkinsonâ s disease dementia

, 2016
Details of the study results. This file provided detailed results of meta-analysis of each risk factor. (DOCX 159 kb)
Yaqian Xu, Yang, Jing, Huifang Shang
openaire   +1 more source

Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36 [PDF]

, 2001
Kufor-Rakeb syndrome is an autosomal recessive nigro-striatal-pallidal-pyramidal neurodegeneration. The onset is in the teenage years with clinical features of Parkinson’s disease plus spasticity, supranuclear upgaze paresis, and dementia.
Al-Din, A., Bond, J., Crow, Y., Hampshire, D.J., Mubaidin, A., Roberts, E., Woods, C.G., Wriekat, A.L.   +7 more
core   +2 more sources

Biomarkers in Parkinson’s disease: A state of the art review

Biomarkers in Neuropsychiatry, 2023
Biomarkers in Parkinson’s disease are widely researched in the field of neuropsychiatry. Though Parkinson’s disease is diagnosed clinically, biomarkers prove to be a promising means to identify disease in early stages, track disease progression, and ...
Kyla Y. Yamashita, Sweta Bhoopatiraju, Bret D. Silverglate, George T. Grossberg   +3 more
doaj   +1 more source

Additional file 1: of Meta-analysis of risk factors for Parkinsonâ s disease dementia

, 2016
Details of studies included in the meta-analysis. This file included details of all studies included in this meta-analysis, categorized by risk factors. Details including first author, year of publication, country, study design, number of participants and NOS scores. (DOCX 119 kb)
Yaqian Xu, Yang, Jing, Huifang Shang
openaire   +1 more source

Atypical parkinsonism: An Update. [PDF]

, 2013
Purpose of review: This update discusses novel aspects on genetics, diagnosis, and treatments of atypical parkinsonism published over the past 2 years. Recent findings: A genome-wide association study identified new genetic risk factors for progressive ...
Hoeglinger, GU, Stamelou, M
core   +1 more source

Detecting cognitive impairment in patients with Parkinson's disease using a brief cognitive screening tool: Addenbrooke's Cognitive Examination (ACE)

Dementia & Neuropsychologia
Detecting cognitive impairment in patients with Parkinson's disease is crucial for good clinical practice given the new therapeutic possibilities available.
Anabel Chade, María Roca, Teresa Torralva, Ezequiel Gleichgerrcht, Nicolás Fabbro, Gonzalo Gómez Arévalo, Oscar Gershanik, Facundo Manes   +7 more
doaj   +1 more source

Additional file 4: Table S2. of Guidelines for dementia or Parkinsonâ s disease with depression or anxiety: a systematic review

, 2016
Mean Domain Question Scores From AGREE II Evaluation. (DOCX 16Â kb)
Goodarzi, Zahra, Mele, Bria, Selynne Guo, Hanson, Heather, Jette, Nathalie, Patten, Scott, Pringsheim, Tamara, Jayna Holroyd-Leduc   +7 more
openaire   +1 more source

Protective potential of glucagon like peptide 2 (GLP-2) against the neurodegeneration [PDF]

, 2019
Neurodegeneration consists in loss of neuron specific types, pattern and distribution, leading to progressive dysfunctions of the central nervous system.
Amato, Antonella, Mulè, Flavia
core   +1 more source

Assessment of genetic risk for improved clinical-neuropathological correlations

Acta Neuropathologica Communications, 2020
In the clinical diagnosis of dementia with Lewy bodies, distinction from Alzheimer’s disease is suboptimal and complicated by shared genetic risk factors and frequent co-pathology.
Barbara E. Spencer, Robin G. Jennings, Chun C. Fan, James B. Brewer   +3 more
doaj   +1 more source